In an attempt to foster debate on whether firms' commitment to ESG policies affects stocks risk-adjusted performance, we analysed the blue-chips of the European countries most affected by COVID-19. We found statistical evidence that companies that follow high ESG standards outperformed low ESG-ranked firms during Phase 1 of COVID-19. In particular, the dampening effect on the downside stock market movement was more evident during the first part of Phase 1 characterized by the sudden crash of stock prices.
Is ESG-ness the vaccine?
Fabio Pizzutilo
2023-01-01
Abstract
In an attempt to foster debate on whether firms' commitment to ESG policies affects stocks risk-adjusted performance, we analysed the blue-chips of the European countries most affected by COVID-19. We found statistical evidence that companies that follow high ESG standards outperformed low ESG-ranked firms during Phase 1 of COVID-19. In particular, the dampening effect on the downside stock market movement was more evident during the first part of Phase 1 characterized by the sudden crash of stock prices.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Is ESG ness the vaccine_vol 30_2023.pdf
non disponibili
Tipologia:
Documento in Versione Editoriale
Licenza:
Copyright dell'editore
Dimensione
519.44 kB
Formato
Adobe PDF
|
519.44 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
